FZD5: A Protein Implicated in Cancer, Neurodegenerative Diseases

Target Name: FZD5

NCBI ID: G7855

FZD5: A Protein Implicated in Cancer, Neurodegenerative Diseases

FZD5 (Fused Zinc Dimer) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a key regulator of cell growth and differentiation, and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of FZD5 is its role in cell signaling. It is a protein that can interact with a variety of transcription factors, including NF-kappa-B, AP-1, and STAT3. These transcription factors are responsible for turning on or off the genes that are responsible for the expression of many different proteins.

FZD5 has been shown to play a role in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of FZD5 are associated with an increased risk of certain types of cancer, such as lung and ovarian cancer.

FZD5 has also been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Studies have shown that FZD5 is expressed in the brains of people with these conditions, and that it is involved in the progression of the disease.

In addition to its role in disease, FZD5 is also a potential drug target. Researchers have identified a number of small molecules that can interact with FZD5 and are being explored as potential therapeutic compounds. These compounds are thought to work by inhibiting the activity of FZD5 or by interacting with it in a way that protects against its effects.

One of the most promising of these compounds is a compound called FZD5-201, which is currently being tested as a potential therapeutic for Alzheimer's disease. Studies have shown that FZD5-201 is able to inhibit the activity of FZD5 and protect against its toxic effects in animal models of Alzheimer's disease.

Another promising compound is a drug called FZD5-13, which is also being tested as a potential therapeutic for neurodegenerative diseases. Studies have shown that FZD5-13 is able to protect against the toxic effects of neurotoxins in animal models of Parkinson's disease.

While the potential therapeutic applications of FZD5 and its associated compounds are still being explored, it is clear that FZD5 is an important protein with a role in the regulation of cell growth and differentiation, and that its dysfunction is implicated in a number of diseases. Further research is needed to fully understand the role of FZD5 in these diseases and to develop effective therapies based on its properties.

Protein Name: Frizzled Class Receptor 5

Functions: Receptor for Wnt proteins (PubMed:9054360, PubMed:10097073, PubMed:20530549). Can activate WNT2, WNT10B, WNT5A, but not WNT2B or WNT4 (in vitro); the in vivo situation may be different since not all of these are known to be coexpressed (By similarity). In neurons, activation of WNT7A promotes formation of synapses (PubMed:20530549). Functions in the canonical Wnt/beta-catenin signaling pathway. The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes (By similarity). A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues (Probable). Plays a role in yolk sac angiogenesis and in placental vascularization (By similarity)

More Common Targets